Study #2023-0036
A Phase I open-label, multicenter study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of SAIL66 in patients with CLDN6-positive locally advanced or metastatic solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
SAIL66, Obinutuzumab
Description
This is a Phase 1 dose-escalation and expansion study that will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of SAIL66 in patients with CLDN6-positive locally advanced or metastatic solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumor
Study phase:
Phase I
Physician name:
Sarina Piha-Paul
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-581-8877
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.